To participate in today's conference call at 4:30 p.m. ET (1:30 p.m. ET), please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll), or access a live audio webcast here: $MTNB

Matinas reports financial results for the three and six months ended June 30, 2024 and provides a business update. The Company will host a conference call and webcast today beginning at 4:30 p.m. ET. For dial-in and webcast details, please visit: $MTNB

Matinas will host a conference call and webcast to discuss Q2 2024 financial results and provide a business update tomorrow, August 14th at 4:30 p.m. ET (1:30 p.m. PT). For details: $MTNB

Matinas will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host a conference call & webcast on that day at 4:30 p.m. ET (1:30 p.m. PT). For details: $MTNB

“We remain very excited by the consistently positive clinical impact of broad-spectrum, oral MAT2203,” said Dr. Matkovits, Matinas' Chief Development Officer. Learn about our Expanded Use Access Program & plans to advance MAT2203 into a Ph. 3 trial: $MTNB

Sharan Yadav, MD, Infectious Disease Fellow, comments on the successful treatment of a patient with limb-threatening Mucor infection in Matinas' oral MAT2203 Compassionate/Expanded Use Access Program: $MTNB

This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203. The patient was treated under Matinas’ Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.

Tune-in today, June 18th at 4 p.m. ET for a fireside chat with antifungal expert Dr. David S. Perlin featuring MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. Register for the event: $MTNB

MAT2203 will be featured in a fireside chat on June 18th. The discussion with #antifungal expert Dr. Perlin will include a review of the antifungal treatment landscape, the advantages of MAT2203 vs. IV-amphotericin B & the MAT2203 market opportunity. $MTNB

Matinas's MAT2203 will be featured in a fireside chat hosted by A.G.P with antifungal expert Dr. David S. Perlin on Tuesday, June 18th at 4 p.m. ET. For details: $MTNB

Matinas announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics. For details: $MTNB #TIDESUSA

Our CEO Jerome D. Jabbour comments on plans to advance MAT2203 into the ORALTO trial in invasive aspergillosis as well as MAT2203's potential to change the treatment paradigm for a variety of invasive fungal infections. For key updates: $MTNB

Attending the ASGCT 27th Annual Meeting? Our Chief Medical Officer, Dr. Ferguson, will be presenting two abstracts featuring Matinas’ LNC platform for the delivery of small oligonucleotides today, May 10th. For more info: $MTNB #ASGCT2024

To participate in today's conference call at 4:30 p.m. ET, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll), or access a live audio webcast here: $MTNB

Matinas reports financial results for the three months ending March 31, 2024 and provides a business update. The Company will host a conference call and webcast today beginning at 4:30 p.m. ET. For dial-in and webcast details, please visit: $MTNB

Matinas will host a conference call and webcast to discuss Q1 2024 financial results and provide a business update tomorrow, May 9th at 4:30 p.m. ET (1:30 p.m. PT). For details: $MTNB

Matinas CMO, Dr. James J. Ferguson, will be presenting 2 abstracts at #ASGCT2024 highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas’ LNC platform for the uptake and targeted delivery of small oligonucleotides. $MTNB

Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. ET (1:30 p.m. PT). For webcast details: $MTNB